Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZLNA.OL
SELLREMOVEZelluna ASA · Healthcare · Norway · $51M · Avg Vol: $260K/d
An early-stage biotech company with no proven commercial products or cash flows. It fails our fundamental quality screens and does not offer a predictable reinvestment runway.
COMPANY DESCRIPTION
Zelluna Immunotherapy AS is a clinical-stage biotechnology company developing allogeneic T-cell receptor (TCR) guided Natural Killer (TCR-NK) cell therapies for solid tumors. The company's proprietary platform combines the targeting specificity of TCRs with the innate killing capacity of NK cells. Its competitive advantage lies in its pioneering position in the TCR-NK space and its robust intellectual property portfolio.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 5,470 | 0 | — |
| EPS | -0.66 | -0.74 | -0.10 | -0.73 | — |
| Shares | 26.3M | 26.3M | 26.3M | 26.3M | 0.0% |
| Debt | 0.6M | 0.4M | 0.2M | 0 | -38.2% |
| Equity | 46.4M | 28.8M | 8.4M | 31.0M | -12.6% |
| Op CF | -17.3M | -19.6M | -10.3M | -15.4M | — |
| Inv CF | 0.9M | 1.4M | -0.8M | 9.8M | — |
| Fin CF | 0.4M | -0.2M | 0.8M | 10.9M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZLNA.OL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZLNA.OL | Zelluna ASA(you) | $51M | 20 | SELL |
| TRMED.OL | Thor Medical ASA | $157M | 20 | SELL |
| CRNA.OL | Circio Holding ASA | $232M | 20 | SELL |
| AZT.OL | ArcticZymes Technologies ASA | $107M | 45 | HOLD |
| NYKD.OL | Nykode Therapeutics AS | $109M | 46 | HOLD |
| PHO.OL | Photocure ASA | $166M | 70 | BUY |
| VISTN.OL | Vistin Pharma ASA | $93M | 99 | STRONG BUY |
| MEDI.OL | Medistim ASA | $438M | 86 | STRONG BUY |
Peer medians: ROE 16.1% · P/E 23.0x · Gross margin 93.6%